pharmaphorum22h
Roche trumpets new fenebrutinib data in relapsing MS
The positive readout comes right after Sanofi revealed that its oral BTK drug tolebrutinib failed ... disability progression in people with multiple sclerosis," said Levi Garraway, Roche's chief ...
Applied Clinical Trials Online7h
API-CAT Trial Shows Reduced-Dose Eliquis Matches Full Dose in Preventing Venous Thromboembolism, Lowers Bleeding Risk in Cancer Patients
The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...
TG Therapeutics rises after trial setback for high dose version of Roche’s MS drug
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Wednesday that a Phase 3 trial for a high-dose version of its multiple sclerosis ...
pharmaphorum22h
Biogen bulks up pipeline with Sage drugs in $3bn deal
Meanwhile, Biogen has suffered recent setbacks including the failures of multiple sclerosis candidate opicinumab and a gene therapy for spinal muscular atrophy (SMA) – at a time when its big ...